Skip to content

Study · Randomized controlled trial · n = 20 · 2015

12 results

Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.

Becker RH, Stechl J, Steinstraesser A, Golor G, Pellissier F

Diabetes/metabolism research and reviews23 Apr 2015Cited by 42 (Europe PMC)

PMID25773712 (opens in a new tab)PMCIDPMC4744661 (opens in a new tab)DOI10.1002/dmrr.2647 (opens in a new tab)PepBankPUB-25773712
Read at sourcePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy subjects, lixisenatide dose-proportionally reduced postprandial glucose versus placebo for up to 6 h.

    In plain wordsIn healthy subjects, lixisenatide reduced blood sugar after a meal versus placebo for up to 6 h.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial plasma glucose
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5, 5, 10 or 20 µg · subcutaneous · single doseAs given in this study (human).

    Measurements

    Duration of postprandial reduction versus placebo
    ≤ 6 h
    lixisenatide versus placebo after standardized meal

    Source sentences

    Summary
    After the meal, postprandial plasma glucose, insulin and C-peptide were dose proportionally reduced with lixisenatide versus placebo for up to 6 h.
    1 context sentence
    Summary · context
    Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout.
  2. 02HumanRandomized controlled trialMechanism

    In healthy subjects, lixisenatide dose-proportionally reduced postprandial insulin versus placebo for up to 6 h.

    In plain wordsIn healthy subjects, lixisenatide reduced insulin after a meal versus placebo for up to 6 h.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial insulin
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5, 5, 10 or 20 µg · subcutaneous · single doseAs given in this study (human).

    Measurements

    Duration of postprandial reduction versus placebo
    ≤ 6 h
    lixisenatide versus placebo after standardized meal

    Source sentences

    Summary
    After the meal, postprandial plasma glucose, insulin and C-peptide were dose proportionally reduced with lixisenatide versus placebo for up to 6 h.
    1 context sentence
    Summary · context
    Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout.
  3. 03HumanRandomized controlled trialMechanism

    In healthy subjects, lixisenatide dose-proportionally reduced postprandial C-peptide versus placebo for up to 6 h.

    In plain wordsIn healthy subjects, lixisenatide reduced C-peptide after a meal versus placebo for up to 6 h.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial C-peptide
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5, 5, 10 or 20 µg · subcutaneous · single doseAs given in this study (human).

    Measurements

    Duration of postprandial reduction versus placebo
    ≤ 6 h
    lixisenatide versus placebo after standardized meal

    Source sentences

    Summary
    After the meal, postprandial plasma glucose, insulin and C-peptide were dose proportionally reduced with lixisenatide versus placebo for up to 6 h.
    1 context sentence
    Summary · context
    Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout.
  4. 04HumanRandomized controlled trialMechanism

    In healthy subjects, lixisenatide transiently lowered glucagon versus placebo, with sustained postmeal reductions and no apparent dose trend.

    In plain wordsIn healthy subjects, lixisenatide lowered glucagon versus placebo, with longer reductions after the meal and no clear dose trend.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGlucagon levels
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5, 5, 10 or 20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, glucagon levels were transiently lower after any lixisenatide dose, with more sustained reductions after the meal and no apparent dose-related trends.
    1 context sentence
    Summary · context
    Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout.
  5. 05HumanRandomized controlled trialMechanism

    In healthy subjects, lixisenatide significantly reduced acetaminophen absorption versus placebo at doses ≥5 µg.

    In plain wordsIn healthy subjects, lixisenatide doses ≥5 µg reduced acetaminophen absorption versus placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreaseAcetaminophen absorption extent
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    ≥5 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Acetaminophen absorption was significantly reduced and delayed compared with placebo for lixisenatide doses ≥5 µg and demonstrated dose-dependent slowing of gastric emptying.
    1 context sentence
    Summary · context
    Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout.
  6. 06HumanRandomized controlled trialMechanism

    In healthy subjects, lixisenatide significantly delayed acetaminophen absorption versus placebo at doses ≥5 µg.

    In plain wordsIn healthy subjects, lixisenatide doses ≥5 µg delayed acetaminophen absorption versus placebo.

    Peptide
    Lixisenatide
    Outcome
    IncreaseAcetaminophen absorption delay
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    ≥5 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Acetaminophen absorption was significantly reduced and delayed compared with placebo for lixisenatide doses ≥5 µg and demonstrated dose-dependent slowing of gastric emptying.
    1 context sentence
    Summary · context
    Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout.
  7. 07HumanRandomized controlled trialMechanism

    In healthy subjects, acetaminophen absorption demonstrated dose-dependent slowing of gastric emptying with lixisenatide versus placebo.

    In plain wordsIn healthy subjects, acetaminophen absorption indicated that lixisenatide slowed stomach emptying versus placebo as dose increased.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGastric emptying rate
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    ≥5 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Acetaminophen absorption was significantly reduced and delayed compared with placebo for lixisenatide doses ≥5 µg and demonstrated dose-dependent slowing of gastric emptying.
    1 context sentence
    Summary · context
    Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout.
  8. 08HumanRandomized controlled trialPharmacokinetics

    In healthy subjects, lixisenatide exposure was nearly dose-proportional.

    In plain wordsIn healthy subjects, lixisenatide exposure increased almost in proportion to dose.

    Peptide
    Lixisenatide
    Outcome
    IncreaseDose proportionality of exposure
    Study

    n = 20

    Comparator
    Increasing lixisenatide dose
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    2.5, 5, 10 or 20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Lixisenatide displayed near dose-proportional exposure, with gastrointestinal events increasing with dose.
    1 context sentence
    Summary · context
    Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout.
  9. 09HumanRandomized controlled trialSafety outcome

    In healthy subjects, gastrointestinal events increased with lixisenatide dose.

    In plain wordsIn healthy subjects, digestive side effects increased as lixisenatide dose increased.

    Peptide
    Lixisenatide
    Outcome
    IncreaseGastrointestinal events by dose
    Study

    n = 20

    Comparator
    Increasing lixisenatide dose
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.5, 5, 10 or 20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Lixisenatide displayed near dose-proportional exposure, with gastrointestinal events increasing with dose.
    1 context sentence
    Summary · context
    Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout.
  10. 10HumanNon-randomized trialMechanism

    In healthy subjects, insulin transiently increased after lixisenatide before the meal.

    In plain wordsIn healthy subjects, insulin briefly increased after lixisenatide before the meal.

    Peptide
    Lixisenatide
    Outcome
    IncreasePremeal insulin
    Study

    n = 20

    Comparator
    Before administration
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5, 5, 10 or 20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    After lixisenatide administration and prior to the standardized meal, insulin and C-peptide transiently increased, while fasting plasma glucose decreased in a dose-dependent manner.
    1 context sentence
    Summary · context
    Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout.
  11. 11HumanNon-randomized trialMechanism

    In healthy subjects, C-peptide transiently increased after lixisenatide before the meal.

    In plain wordsIn healthy subjects, C-peptide briefly increased after lixisenatide before the meal.

    Peptide
    Lixisenatide
    Outcome
    IncreasePremeal C-peptide
    Study

    n = 20

    Comparator
    Before administration
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5, 5, 10 or 20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    After lixisenatide administration and prior to the standardized meal, insulin and C-peptide transiently increased, while fasting plasma glucose decreased in a dose-dependent manner.
    1 context sentence
    Summary · context
    Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout.
  12. 12HumanNon-randomized trialEfficacy outcome

    In healthy subjects, fasting glucose decreased dose-dependently after lixisenatide before the meal.

    In plain wordsIn healthy subjects, fasting blood sugar decreased with increasing lixisenatide doses before the meal.

    Peptide
    Lixisenatide
    Outcome
    DecreaseFasting plasma glucose
    Study

    n = 20

    Comparator
    Before administration
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5, 5, 10 or 20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    After lixisenatide administration and prior to the standardized meal, insulin and C-peptide transiently increased, while fasting plasma glucose decreased in a dose-dependent manner.
    1 context sentence
    Summary · context
    Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.